Completed PHASE2 INTERVENTIONAL 2-arm NCT01303835

Low Dose Naltrexone for Glioma Patients

Effects of Low Dose Naltrexone on Quality of Life in High Grade Glioma Patients: A Placebo-Controlled, Double-Blind Randomized Trial

Sponsor: Katy Peters

Conditions Malignant Glioma

Interventions LDN Placebo

Updated 8 times since 2017 Last updated: Jun 25, 2015 Started: May 31, 2011 Primary completion: Jun 30, 2014 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01303835, this PHASE2 trial focuses on Malignant Glioma and remains completed. Sponsored by Katy Peters, it has been updated 8 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Katy Peters

Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Durham, United States